Amifostine (CAS 20537-88-6)
See product citations (6)
QUICK LINKS
Amifostine is a chemical compound extensively studied in the context of cellular protection mechanisms. It is utilized to explore the protection of normal cells during exposure to certain types of stress. In laboratory applications, Amifostine is applied to understand its modulatory effects on DNA repair pathways, as well as its ability to scavenge reactive oxygen species that can cause cellular damage. Investigations into the biochemical pathways influenced by Amifostine have provided insights into the cellular responses to oxidative stress and the potential enhancement of DNA repair mechanisms. Additionally, Amifostine is of interest in the study of radiobiology, where it is used to examine the selective protection of healthy cells in contrast to those undergoing abnormal growth or division, thereby contributing to a broader understanding of cellular resilience.
Amifostine (CAS 20537-88-6) References
- In vivo amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients. | Provinciali, M., et al. 1999. Life Sci. 64: 1525-32. PMID: 10353617
- Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review). | Orditura, M., et al. 1999. Oncol Rep. 6: 1357-62. PMID: 10523712
- The potential of amifostine: from cytoprotectant to therapeutic agent. | Santini, V. and Giles, FJ. 1999. Haematologica. 84: 1035-42. PMID: 10553165
- Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. | Capizzi, RL. and Oster, W. 2000. Int J Hematol. 72: 425-35. PMID: 11197208
- Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. | Maurici, D., et al. 2001. Oncogene. 20: 3533-40. PMID: 11429700
- Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. | Andreassen, CN., et al. 2003. Semin Radiat Oncol. 13: 62-72. PMID: 12520465
- Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 alpha. | Koukourakis, MI., et al. 2004. Cancer Chemother Pharmacol. 53: 8-14. PMID: 14574457
- The role of amifostine in the treatment of carcinoma of the uterine cervix: an update of RTOG-0116 and review of future directions. | De Los Santos, JF. and Small, W. 2004. Semin Oncol. 31: 37-41. PMID: 15726521
- Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. | Ma, C., et al. 2010. Eur J Nucl Med Mol Imaging. 37: 1778-85. PMID: 20130857
- Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis. | Devine, A. and Marignol, L. 2016. Anticancer Res. 36: 5-12. PMID: 26722022
- The efficacy and safety of amifostine for the acute radiation syndrome. | Singh, VK. and Seed, TM. 2019. Expert Opin Drug Saf. 18: 1077-1090. PMID: 31526195
- The role of amifostine in preventing radiotherapy induced testicular tissue damage in rats. | Gezer, A. and Karadag-Sari, E. 2022. Biotech Histochem. 97: 215-221. PMID: 34058938
- Could Amifostine Prevent Experimental Radiotherapy-Induced Acute Pericarditis? | Bahat, Z., et al. 2022. Asian Pac J Cancer Prev. 23: 3209-3213. PMID: 36172686
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Amifostine, 10 mg | sc-200937 | 10 mg | $79.00 | |||
Amifostine, 50 mg | sc-200937A | 50 mg | $311.00 |